KANBO Biotech 2025 Q4 Financials
KANBO Biotech (6919), a biotechnology and medical care company, reported a basic EPS of -0.23 NTD for Q4 2025, with operating revenue of 0.038 billion NTD and a net loss of 0.352 billion NTD after tax.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 8, 2026 at 08:00 (3071h 0m after Published)
- 🤖 AI Analyzed: April 11, 2026 at 21:07 (85h 7m after Collected)
Company Code: 6919. Company Name: KANBO Biotech Co., Ltd. Industry: Biotechnology and Medical Care. Year/Quarter: 2025 Q4. Basic Earnings Per Share: -0.23 NTD. Operating Revenue: 0.038 billion NTD. Net Income After Tax: -0.352 billion NTD.
FAQ
康霈生技在2025年第四季的獲利狀況如何？
該公司在2025年第四季稅後淨利為-3.52億元，基本每股盈餘為-0.23元。
What was Kang Pei Biotech's profitability in Q4 2025?
In the fourth quarter of 2025, the company reported a net profit after tax of -3.52 billion yuan and basic earnings per share of -0.23 yuan.
康霈生技の2025年第4四半期の収益状況はどうでしたか？
同社は2025年第4四半期に、税引後純利益-3.52億元、1株当たり純利益（EPS）-0.23元を記録しました。